RESEARCH MOTIVATION

Metastatic gastric cancer has a very poor prognosis and a low 5-year survial rate. lts incidence is particularly high in East Asia, highlighting a strong need for new therapeutic strategies

Limitations of Current Treatment and Unmet Needs

Current management relies mainly on surgery and systemic chemother apy, yet outcomes for metastatio disease remain limited. In addition, the heterogeneity of gastric cancer has hindered the establishment of robust biomarkers for targeted therapy

EPB41L5 and the Mechanism of Metastasis

EMT iS a key process driving gastric cancer metastasis, and EPB41L5 shows elevated expression in patient groups associated with poor prognosis While EPB41L5-related signaling has been implicated in metastasis in other cancers, its function and clinical relevance in gastric cancer remain insufficiently defined-this study aims to address that gap

CERTIFICATION

Our intellectual property portfolio reflects our commitment to innovation and clinical impact. The following patents protect our core technologies and their applications, strengthening our competitive advantage ang supporting future partnerships and commercialization

[Reg] Patent - KR

10-2125703

EPB41L5 단백질의 에피토프 및 단일 클론항체

[Reg] Patent - KR

10-2268847

EPB41L5 단백질의 에피토프 및 단일클론항체

[Reg] Patent - KR

10-2268846

EPB41L5 단백질의 에피토프 및 단일클론항체

[Reg] Patent - USA

US 12357690 B2

EPITOPE OF EPB41L5, AND MONOCLONAL ANTIBODY

[Reg] Patent - China

CN 112638939 B

一种EPB41L5的表位及单克隆抗体

[Pub] Patent - WIPO (PCT)

WO 2020 / 032614 A1

EPB41L5 단백질의 에피토프 및 단일클론항체

[Pub] Pantent - EU

EP 3 835 317 A1

EPITOPE OF EPB41L5, AND MONOCLONAL ANTIBODY

[Pub] Patent - JP

JP 2021 - 533817A

Ｅｐｂ４１ｌ５タンパク質のエピトープおよび単クローン抗体

NOTICE

Antibody Treatment Preclinical Transfer Suppression Performance [Newdaily]

In a New Daily article, Busan-based deep-tech bio venture Cellaster Inc. announced on the 15th that …
LATEST NOTICE

New PAGE!!

 Cellaster Homepage has been renewed and came back!!

Cellsater IR Brief (for BIBAN)

 Cellaster has been to Saudi BIBAN!

HISTORY

  • 2018 11
    • company Establishment
  • 2019 05
    • Acquire CAP-1 related rights
  • 2020 06
    • Patent Registration (Paratope)
  • 2021 03
    • [CAP-1] Initiating developments of αEPB41L5 mAbs
  • 2021 06
    • Renaming Company
    • Patent Registration (epitope, component)
  • 2021 09
    • Capital Raise (Over $1 Million)
    • Designated as a company with excellent technical capabilities
  • 2022 09
    • [CAP-1] Secure some fully human mAb
  • 2023 12
    • [CAP-1] Secure some humanized mAb
    • Designated as a national R&D project (Deep Tech Tips) and in progress (Jul. 2024- Jun. 2026)
    • Designated as a venture company
  • 2024 02
    • Acquired the permission of establishing a R&D center
  • 2024 09
    • [CAP-1] In vitro experiments to check efficacies of mAbs
    • [CAP-1] Preparing PDO/PDX/CDX experiments
    • [CAP-1] Preparing MoA study

CONTACT

COMPANY

Name
CELLASTER, Inc.
Capital
Over US$ 1 Million
CEO
Dr. JANG HO-YEON
Established
08 Nov 2018

ADDRESS

H.Q.
#101-ho, 45, Centum dong-ro, Haeundae-gu, Busan, Republic of Korea
Research
#A21-ho, 194-25, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea

CONTACT

E-mail
info@cellaster.com